Your session is about to expire
← Back to Search
Other
Microcurrent Treatment for Chronic Debilitating Pain
N/A
Waitlist Available
Research Sponsored by Paul Crawford
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up screening, time 0 (week 0), time 1 (week 1), time 2 (week 2), time 3 (week 3), time 4 (week 4), time 5 (week 5), time 6 (week 12)
Summary
This trial compares standard pain treatment with and without microcurrent therapy in primary care patients. It aims to see if microcurrent therapy can be more effective in reducing pain by using tiny electrical currents to stimulate healing. Microcurrent therapy has been studied for its potential to increase function and decrease pain in people with acute knee pain.
Eligible Conditions
- Pain
- Opioid Use Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ screening
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screening
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Defense and Veterans Pain Rating Scale (DVPRS)
Measure Yourself Medical Outcome Profile (MYMOP)
Patient-Reported Outcomes Information System (PROMIS) -57 Profile standardized T-Scores
Secondary study objectives
Opioids taken
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Standard treatment + Microcurrent TherapyExperimental Treatment1 Intervention
100-300µA microcurrent delivered for 20-300 minutes, once a week for 6 weeks
Group II: Standard treatment + placeboPlacebo Group1 Intervention
Placing the microcurrent pads on the patient but not turning on the microcurrent box for 30 minutes once a week for 6 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Standard treatment + Microcurrent Therapy
2019
N/A
~200
Find a Location
Who is running the clinical trial?
Paul CrawfordLead Sponsor
5 Previous Clinical Trials
767 Total Patients Enrolled